Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $23,681.43 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CTO David Badawi sold 5,679 shares of the firm's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.17, for a total value of $23,681.43. Following the transaction, the chief technology officer directly owned 1,831,025 shares in the company, valued at approximately $7,635,374.25. This represents a 0.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sight Sciences Stock Performance

SGHT traded down $0.74 during trading on Monday, reaching $3.47. The company's stock had a trading volume of 267,059 shares, compared to its average volume of 213,085. The company's fifty day moving average price is $3.71 and its 200-day moving average price is $3.13. The company has a market capitalization of $179.40 million, a price-to-earnings ratio of -3.54 and a beta of 2.47. The company has a debt-to-equity ratio of 0.51, a quick ratio of 9.99 and a current ratio of 10.47. Sight Sciences, Inc. has a 52-week low of $2.03 and a 52-week high of $8.45.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.01. The business had revenue of $17.51 million for the quarter, compared to analyst estimates of $16.51 million. Sight Sciences had a negative return on equity of 54.62% and a negative net margin of 63.24%. On average, equities analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

Institutional investors have recently modified their holdings of the company. Foster Victor Wealth Advisors LLC acquired a new position in shares of Sight Sciences during the 1st quarter worth approximately $85,000. Renaissance Technologies LLC raised its position in shares of Sight Sciences by 654.3% during the 4th quarter. Renaissance Technologies LLC now owns 393,006 shares of the company's stock worth $1,431,000 after purchasing an additional 340,906 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Sight Sciences by 53.4% during the 4th quarter. Wells Fargo & Company MN now owns 16,600 shares of the company's stock worth $60,000 after purchasing an additional 5,781 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Sight Sciences by 79.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 243,954 shares of the company's stock worth $887,000 after purchasing an additional 108,001 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Sight Sciences during the 4th quarter worth approximately $464,000. Hedge funds and other institutional investors own 55.51% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SGHT. Wall Street Zen raised Sight Sciences from a "sell" rating to a "hold" rating in a report on Saturday, June 28th. Needham & Company LLC reissued a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th. Piper Sandler reissued a "neutral" rating and set a $4.00 price target (up previously from $3.50) on shares of Sight Sciences in a report on Wednesday, June 18th. Lake Street Capital lifted their price objective on Sight Sciences from $2.50 to $3.00 and gave the company a "hold" rating in a report on Friday, May 9th. Finally, Citigroup reaffirmed a "neutral" rating and issued a $3.60 price objective (up previously from $3.20) on shares of Sight Sciences in a report on Thursday, May 22nd. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $4.10.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.